These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8146063)

  • 21. [Prenatal diagnosis of Down's syndrome: prediction from maternal serum markers].
    Zilberstein T; Maymon E
    Harefuah; 1998 Mar; 134(5):393-6. PubMed ID: 10909560
    [No Abstract]   [Full Text] [Related]  

  • 22. [Down's syndrome - twins - malignant tumors: 3 results of a single cause in 35- to 39-year-old women?].
    Kucera J
    Cesk Gynekol; 1980; 45(10):755-8. PubMed ID: 6451310
    [No Abstract]   [Full Text] [Related]  

  • 23. The sensitivity of the trivariate analysis using maternal serum alpha-feto protein, human chorionic gonadotrophin and maternal age in screening for fetal aneuploidy in mothers above the age of 35.
    Anandakumar C; Chew S; Wong YC; Goh VH; Tain CF; Ratnam SS
    J Perinat Med; 1999; 27(3):178-82. PubMed ID: 10503178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for Down's syndrome. Statistical modelling is best tool for formulating screening policy.
    Cuckle H
    BMJ; 2000 Sep; 321(7263):763; author reply 764-5. PubMed ID: 10999926
    [No Abstract]   [Full Text] [Related]  

  • 25. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
    Wald NJ; Watt HC
    Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Etiology of Down's syndrome (mongolism)].
    Neuhäuser G
    Hippokrates; 1978 Feb; 49(1):84-6. PubMed ID: 147254
    [No Abstract]   [Full Text] [Related]  

  • 27. [The age-dependent incidence of Down's syndrome and the free-radical theory].
    Arbuzova SB
    Tsitol Genet; 1996; 30(5):27-35. PubMed ID: 9026987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for Down's syndrome. Serum screening programmes are effective and safe.
    Wald NJ; Hackshaw AK; Huttly W
    BMJ; 2000 Sep; 321(7263):763-4; author reply 764-5. PubMed ID: 10999927
    [No Abstract]   [Full Text] [Related]  

  • 29. Screening for Down's syndrome. Data do not support study's claim.
    Norgaard-Pedersen B
    BMJ; 2000 Sep; 321(7263):763; author reply 764-5. PubMed ID: 10999925
    [No Abstract]   [Full Text] [Related]  

  • 30. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input.
    Reynolds T; Ellis A; Jones R
    Ann Clin Biochem; 2004 Nov; 41(Pt 6):464-8. PubMed ID: 15588435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What you need to know about... Down's syndrome.
    Nurs Times; 2003 Jun 3-9; 99(22):28. PubMed ID: 12808746
    [No Abstract]   [Full Text] [Related]  

  • 32. Age-independent indices in second-trimester serum screening for Down's syndrome are useless.
    Zimmermann R; Reynolds TM; John R; Spencer K; Bartels I; Coombes E; Trevor S
    Prenat Diagn; 1996 Jan; 16(1):79-82. PubMed ID: 8821858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late pregnancy risks.
    Am Fam Physician; 1983 Dec; 28(6):244. PubMed ID: 6228131
    [No Abstract]   [Full Text] [Related]  

  • 34. Down's syndrome and maternal smoking in early pregnancy.
    Källén K
    Genet Epidemiol; 1997; 14(1):77-84. PubMed ID: 9055063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
    Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The prenatal diagnosis of Down's syndrome based on the biochemical screening of maternal serum markers].
    Arbuzova SB; Nikolenko MI; Khlevnaia LA; Fedotova OO; Solov'eva VD; Malova SA
    Tsitol Genet; 1998; 32(1):66-71. PubMed ID: 9695254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
    Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
    Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prenatal screening for Down's syndrome].
    Qin Q; Christiansen M; Norgaard-Pedersen B
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):694-7. PubMed ID: 9639772
    [No Abstract]   [Full Text] [Related]  

  • 39. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corrections to maternal age-specific live birth prevalence of Down's syndrome.
    Morris J; Mutton D; Alberman E
    J Med Screen; 2005; 12(4):202. PubMed ID: 16417698
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.